C84.6A
BillableAnaplastic large cell lymphoma, ALK-positive, in remission
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C84.6A an HCC code?
Yes. C84.6A maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C84.6A
For C84.6A to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C84.6A during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C84.6A is the ICD-10-CM diagnosis code for anaplastic large cell lymphoma, alk-positive, in remission. A type of aggressive lymphoma (cancer of immune cells) with a specific genetic marker (ALK-positive) that is currently in remission, meaning the cancer is not actively growing. C84.6A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C84.6A maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C84.6A maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
The '6A' suffix specifically indicates ALK-positive status and remission status; do not confuse with ALK-negative variants. Because C84.6A maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C84.6A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •The '6A' suffix specifically indicates ALK-positive status and remission status; do not confuse with ALK-negative variants
- •Remission status should be documented in the medical record; clarify with the oncologist if the patient is in complete or partial remission
Clinical Significance
Anaplastic large cell lymphoma, ALK-positive, in remission means the patient achieved disease control after treatment for this ALK-driven lymphoma. ALK-positive ALCL has excellent remission rates (approximately 80-90% complete remission with CHOP-based chemotherapy), but ongoing surveillance is necessary. This code maintains cancer diagnosis for risk adjustment while reflecting current remission status.
Documentation Requirements
- ✓Original pathology confirming ALCL ALK-positive diagnosis
- ✓Oncologist documentation explicitly stating remission (complete or partial)
- ✓Most recent PET/CT or imaging confirming no active disease
- ✓Surveillance plan documented
- ✓Treatment history including chemotherapy regimen received